Hye Lim Jung, M.D. Ph.D.
Blood Res 2016; 51(3): 149-151Young-Ho Lee, M.D. Ph.D., and Wee-Jin Rah, M.D.
Blood Res 2016; 51(3): 152-154Takashi Onaka, and Akihito Yonezawa
Blood Res 2016; 51(3): 155Huma Mansoori, and Bushra Moiz
Blood Res 2016; 51(3): 156Hoibin Jeong, Seoyeon Bok, Beom-Ju Hong, Hyung-Seok Choi, and G-One Ahn
Blood Res 2016; 51(3): 157-163Hyoung Soo Choi, Chang Won Choi, Heon Min Kim, and Hye Won Park
Blood Res 2016; 51(3): 164-170Jung-Hyun Byun, In-Seok Jang, Jong Woo Kim, and Eun-Ha Koh
Blood Res 2016; 51(3): 171-174Hyojeong Kim, Young Mi Seol, Moo-Kon Song, Young Jin Choi, Ho-Jin Shin, Sang Hyuk Park, Eun Yup Lee, and Joo-Seop Chung
Blood Res 2016; 51(3): 175-180Sang-Yong Shin, Seung-Tae Lee, Hyun-Young Kim, Chang-Hun Park, Hee-Jin Kim, Jong-Won Kim, Seok Jin Kim, Won Seog Kim, and Sun-Hee Kim
Blood Res 2016; 51(3): 181-186Ji Young Lee, Sang Min Lee, Moon Young Choi, Ki Hyang Kim, Young Don Joo, Sung Nam Im, and Won Sik Lee
Blood Res 2016; 51(3): 187-192
Overall survival and progression free survival (A) overall survival (B) Progression-free survival.
|@|~(^,^)~|@|Survival curves of NKTCL and non-NKTCL patients.
|@|~(^,^)~|@|Survival curves stratified by end of treatment response.